Latest:
Dr. Mamounas on the Role of Extended Adjuvant Endocrine Therapy in ER+ Breast Cancer
Eleftherios (Terry) P. Mamounas, MD, MPH, FACS, discusses the role of extended adjuvant endocrine receptor–positive breast cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Texas Oncology, US Oncology
Latest:
US Oncology Network Continues Its Rapid Growth and Enhances Surgical Expertise
The US Oncology Network, the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, continues to expand its reach into local communities while broadening its surgical expertise with the addition of physicians from Texas Colon & Rectal Specialists, a large colorectal practice in North Texas, as a part of Texas Oncology, a practice in The Network.
Thanh H. Dellinger, MD
Latest:
Growing Body of Evidence Supports Use of HIPEC in Ovarian Cancer
A large pool of evidence exists to support the use of HIPEC in ovarian cancer, and hyperthermic and other novel intraperitoneal chemotherapies should continue to be incorporated into novel clinical trial designs.
Theodore H. Welling MD
Latest:
Dr. Welling on SIRT in Patients With Hepatobiliary Neoplasms
Theodore H. Welling MD, associate professor, department of Surgery, director, Liver Tumor Program, NYU Langone’s Perlmutter Cancer Center, discusses the use of selective internal radiation therapy (SIRT) in patients with hepatobiliary cancers.
Thierry Conroy, MD
Latest:
Dr. Conroy on the Findings With Adjuvant mFOLFIRINOX in Pancreatic Cancer
Thierry Conroy, MD, medical oncologist, director, Institut de Cancerologie de Lorraine, discusses the findings with an adjuvant a modified FOLFIRINOX regimen in patients with nonmetastatic pancreatic ductal adenocarcinoma.
Thierry Jahan, MD
Latest:
Dr. Thierry Jahan on CRS-207 With Chemotherapy in Mesothelioma
Thierry Jahan, MD, professor of medicine at the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, discusses CRS-20, a live, attenuated Listeria monocytogenes bacterium which is being investigated with chemotherapy in malignant pleural mesothelioma (MPM).
Thierry M. Jahan, MD
Latest:
Dr. Thierry Jahan on the CRS-207 Vaccine in Mesothelioma
Thierry M. Jahan, MD, a clinical professor in the Department of Medicine at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses a phase Ib trial of CRS-207 in malignant pleural mesothelioma (MPM).
Thomas A. Abrams, MD, Harvard Medical School
Latest:
Dr. Abrams on Next Steps for Cabozantinib/Atezolizumab Combo in MSS/MMRp CRC
Thomas A. Abrams, MD, discusses the next steps for exploration of cabozantinib plus atezolizumab in the treatment of microsatellite stable and mismatch repair proficient colorectal cancer.